Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in Diffuse Cutaneous Systemic Sclerosis
NCT04781543Phase 2Terminated
- Sponsor
- Amgen
- Start
- Nov 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in diffuse cutaneous systemic sclerosis (dcSSc) (3 arms), sponsored by Amgen. Primary endpoint: Forced Vital Capacity Percent Predicted at 52 weeks. Started Nov 2021; status: terminated.
02
Drugs
fipaxalparant
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04781543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781543.